AnaptysBio, Inc. (ANAB) Financial Statements
AnaptysBio, Inc. (ANAB) reported trailing twelve-month revenue of $237.6M (up 92.9% year on year) and net income of $195.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $18.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANABAnaptysBio, Inc.Follow ANAB — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.0 | 5.0 | 8.0 | 75.0 | 63.2 | 10.3 | 17.2 | 91.3 | 234.6 | 237.6 | |
| Gross profit | — | — | — | — | — | — | — | 79.8 | — | — | |
| Research & development | 29.4 | 56.2 | 99.3 | 80.0 | 98.5 | 88.8 | 132.3 | 163.8 | 136.0 | — | |
| Operating income | -28.8 | -66.7 | -107.4 | -23.9 | -56.8 | -115.2 | -164.4 | 66.2 | 226.9 | — | |
| Pre-tax income | -30.1 | -61.8 | -97.5 | -19.9 | -57.8 | -128.7 | -163.6 | 31.1 | 162.3 | 235.1 | |
| Income tax | 0.0 | -0.2 | -0.2 | 0.0 | 0.0 | 0.0 | -0.0 | 0.2 | 0.8 | -181.4 | |
| Net income | -30.1 | -61.7 | -97.3 | -19.9 | -57.8 | -128.7 | -163.6 | -145.2 | -13.2 | 195.7 | |
| Diluted EPS ($) | -1.52 | -2.50 | -3.60 | -0.73 | -2.11 | -4.57 | -6.08 | -4.92 | -0.44 | — | |
| Diluted shares (mn) | — | — | — | — | 27.4 | 28.2 | 26.9 | 29.5 | 30.2 | — |
USD millions · SEC XBRL
AnaptysBio, Inc. — questions
- What is AnaptysBio, Inc.'s revenue?
- $237.6M over the twelve months to 2026-06-30, up 92.9% year on year, from its 10-Q and 10-K filings.
- What is AnaptysBio, Inc.'s net income?
- $195.7M over the twelve months to 2026-06-30.
- What is AnaptysBio, Inc.'s free cash flow?
- $18.1M over the twelve months to 2026-06-30.
Every figure on this page comes from AnaptysBio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.